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Abstract
Background: Pseudomonas aeruginosa, an increasingly prevalent opportunistic pathogen, utilizes a
type III secretion system for injection of toxins into host cells in order to initiate infection. A crucial
component of this system is PcrV, which is essential for cytotoxicity and is found both within the
bacterial cytoplasm and localized extracellularly, suggesting that it may play more than one role in
Pseudomonas infectivity. LcrV, the homolog of PcrV in Yersinia, has been proposed to participate in
effector secretion regulation by interacting with LcrG, which may act as a secretion blocker.
Although PcrV also recognizes PcrG within the bacterial cytoplasm, the roles played by the two
proteins in type III secretion in Pseudomonas may be different from the ones suggested for their
Yersinia counterparts.
Results: In this work, we demonstrate by native mass spectrometry that PcrV and PcrG expressed
and purified from E. coli form a 1:1 complex in vitro. Circular dichroism results indicate that PcrG
is highly unstable in the absence of PcrV; in contrast, both PcrV alone and the PcrV:PcrG complex
have high structural integrity. Surface plasmon resonance measurements show that PcrV interacts
with PcrG with nanomolar affinity (15.6 nM) and rapid kinetics, an observation which is valid both
for the full-length form of PcrG (residues 1–98) as well as a form which lacks the C-terminal 24
residues, which are predicted to have low secondary structure content.
Conclusions: PcrV is a crucial component of the type III secretion system of Pseudomonas, but the
way in which it participates in toxin secretion is not understood. Here we have characterized the
interaction between PcrV and PcrG in vitro, and shown that PcrG is highly unstable. However, it
associates readily with PcrV through a region located within its first 74 amino acids to form a high
affinity complex. The fact that PcrV associates and dissociates quickly from an unstable molecule
points to the transient nature of a PcrV:PcrG complex. These results are in agreement with
analyses from pcrV deletion mutants which suggest that PcrV:PcrG may play a different role in
effector secretion than the one described for the LcrV:LcrG complex in Yersinia.
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Pseudomonas aeruginosa is an opportunistic, Gram-nega-
tive bacterium which infects immunocompromised indi-
viduals, such as those suffering from AIDS, cancer, and
severe burns; in addition, it is highly prevalent in the
lungs of patients with cystic fibrosis (CF), being responsi-
ble for a large number of deaths in such cases [1]. P. aeru-
ginosa, like most other Gram-negative pathogens, employs
a type III secretion system (TTSS) to inject toxins into the
cytoplasm of contacted host cells [2]. Such a system
requires more than 20 different proteins, a number of
which are assembled into a "secreton" structure which
spans both bacterial membranes and includes a "needle"
through which effector molecules travel in preparation for
their injection into the target cell [3,4]. Once through the
needle and in the target cytosol, Pseudomonas toxins
(ExoS, ExoT, ExoY, and ExoU) disrupt the actin cytoskele-
ton and signal transduction pathways, eventually causing
cell death [5–7].
The control of effector molecule injection involves a com-
plex regulatory mechanism, a critical component of which
is PcrV, a 32 kDa protein which has both intrabacterial
and extracellular functions [8,9], much as LcrV, its homo-
logue in the well-studied Yersinia TTS system [10]. Both
PcrV and LcrV have been shown to be protective antigens
against infection with their respective pathogens
[9,11,12], and LcrV is currently in phase II trials as the
principal agent of a protective vaccine against plague
(caused by Yersinia pestis; [13]). The expression of both
LcrV and PcrV is transcriptionally up-regulated at 37°C
upon host infection or in vitro by a decrease in calcium,
and the proteins are required for translocation of effector
molecules into the target cytoplasm; in Yersinia, a lcrV null
mutant cannot translocate effector molecules [10,14,15].
LcrV has been shown to interact with LcrG, an 11 kDa
cytoplasmic molecule whose proposed function involves
blockage of the secretion apparatus through interaction
with the secreton macromolecular complex under non-
secreting conditions [16,17]. Interestingly, overexpression
of LcrG inhibits effector secretion even in the presence of
LcrV [18], and a LcrG mutant which is incapable of bind-
ing LcrV continues to block secretion [19]. Thus, a "titra-
tion" model has been proposed in which secretion-prone
conditions cause an increase in LcrV expression, which in
turn binds to LcrG, unblocking the secreton gate [16,18].
Notably, the applicability of this model to Pseudomonas is
improbable, since ∆pcrV strains are able to secrete effector
molecules both under inducing or non-inducing condi-
tions (presence or absence of chelating agents, respec-
tively; [9]), suggesting that the Pseudomonas secreton gate
may not be under the control of the PcrV:PcrG complex,
or that the regulation mechanism may be different.
Recently, it has been shown that PcrG is capable of com-
plementing a lcrG strain, as well as interacting with LcrV
[19,20]; in addition, preliminary affinity immunoblotting
studies have identified an interaction between PcrV and
PcrG [21]. However, to date no biochemical characteriza-
tion of the Pseudomonas PcrV and PcrG proteins, or of the
PcrV:PcrG complex, has been made available. Here, we
have independently expressed and purified PcrV and
PcrG, and isolated a stable PcrV:PcrG complex. Native
mass spectrometry has been used to identify the 1:1
nature of the complex as well as the monomeric state of
PcrV. Notably, both PcrV and the PcrV:PcrG complex are
stable in temperature scanning circular dichroism studies,
while PcrG is highly unstable. Surface plasmon resonance
results show that the PcrV:PcrG complex associates
through rapid kinetics and with nanomolar affinity, but
with values that are clearly distinct from those reported for
the Yersinia LcrV:LcrG complex. These results support a
role for the formation of a transient complex between
PcrV and PcrG as a means of regulating type III secretion
in Pseudomonas which differs from the titration mecha-
nism proposed for the Yersinia system.
Results
Characterization of PcrV and PcrG
PcrV and LcrV, as well as PcrG and LcrG display 42% and
40% sequence identity, respectively (Fig. 1). Secondary
structure prediction calculations for PcrV suggest a helical
structure, with a coiled coil region ranging from residues
113 to 148 (as calculated by the PHD program). For PcrG,
such predictions suggest that the region following residue
74 presents a lower possibility of displaying stable sec-
ondary structure; in addition, studies involving the
LcrV:LcrG complex suggest that the N-terminal domain of
LcrG is responsible for most of the contacts with LcrV [20].
Consequently, in order to independently characterize the
functions of the 1–74 and 75–98 regions of PcrG, we over-
expressed both full-length (amino acids 1–98) and a
shortened version (amino acids 1–74) of the protein. PcrV
(32,633 Da), PcrG (1–98; 11,216 Da) and PcrG (1–74;
8,382 Da) were expressed in the E. coli cytoplasm and
purified by nickel affinity and gel filtration chromatogra-
phies, after which the His tag was removed in the case of
PcrV. PcrV eluted from an Amersham S200 gel filtration
column in 15.5 ml (which corresponds to an approximate
Mr of 38 kDa, based on marker proteins), and native mass
spectrometry performed on purified PcrV confirmed that
the molecule is monomeric (mass obtained, 32,644 Da).
Purified PcrG eluted at 17.4 ml, and when mixed in
approximately equimolar amounts, PcrV and PcrG shifted
their profiles and co-eluted from a gel filtration column at
14.3 ml. This observation provides clear evidence of the
formation of a high affinity complex between the two pro-
teins (Fig. 2). Notably, the 1:1 nature of the PcrV:PcrG
complex was confirmed by native mass spectrometry,Page 2 of 9
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mass for the complex, 43,910 Da).
PcrG is only stable in the presence of PcrV
Limited proteolytic assays performed on PcrG revealed
that a variety of proteases (trypsin, chymotrypsin, elastase,
thrombin, and V8) were able to cleave PcrG into small
peptidic fragments, suggesting that the protein could be
inherently unstable. In addition, initial CD spectra, per-
formed at 20°C, revealed that PcrG had very low elliptic-
ity; measurements performed at 4°C, however, displayed
a better signal, suggesting that at low temperature the pro-
tein could be slightly more stable. Consequently, CD
measurements for PcrV, PcrG, and the PcrV:PcrG complex
were all performed at 4°C. The CD spectra of PcrV and the
PcrV:PcrG complex exhibit a maximum at 192 nm and
minima at 208 and 222 nm, which are characteristic of
proteins with α-helical content (Fig. 3). For PcrV, the esti-
mated helical content is approximately 18% (see Materi-
als & Methods). Notably, the estimated helical content for
PcrG is 6%, suggesting that the uncomplexed protein,
even at 4°C, may be poorly folded. For the PcrV:PcrG
complex, however, the estimated helical content is 25%.
The presence of an increase in the relative percentage of α-
helical content between PcrV and PcrV:PcrG suggests that
PcrG may be stabilized by binding to PcrV.
Sequence alignment between PcrV (P. aeruginosa) and LcrV (Y. pseudotuberculosis), and PcrG and LcrGFig re 1
Sequence alignment between PcrV (P. aeruginosa) and LcrV (Y. pseudotuberculosis), and PcrG and LcrG. Identi-
cal residues are highlighted, and the predicted coiled coil region in PcrV is identified with a green bar. The blue bar represents 
the major antigenic region of LcrV identified in active and passive immunization studies [12]. The arrow points to the end of 
the PcrG (1–74) construct.Page 3 of 9
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revealed that PcrV unfolds in a cooperative manner, pre-
senting a transition melting (Tm) temperature of 65°C,
which is typical of a stable macromolecule (Fig. 4a). PcrG,
however, unfolds in a non-cooperative manner, starting
to unfold already at low temperatures, and does not dis-
play a clear Tm, revealing that the uncomplexed protein
PcrV and PcrG co-migrate in gel filtrationFigure 2
PcrV and PcrG co-migrate in gel filtration. (A) 
PcrV:PcrG peak fraction after proteins were purified individ-
ually and mixed in equimolar amounts prior to gel filtration 
chromatography; (B) PcrV peak fraction; (C) PcrG peak frac-
tion. Positions of Mr markers (kDa) are shown on the left 
side of the gel.
CD spectra for PcrV, PcrG, and PcrV:PcrGFigur  3
CD spectra for PcrV, PcrG, and PcrV:PcrG. Data are 
represented as molar ellipticity and were recorded at 4°C 
and 0.35 mg/ml (PcrV), 0.25 mg/ml (PcrG), and 0.25 mg/ml 
(PcrV:PcrG).
Temperature scanning CD spectra for PcrV, PcrG, and PcrV:PcrGFigur  4
Temperature scanning CD spectra for PcrV, PcrG, 
and PcrV:PcrG. Both PcrV (A) and PcrV:PcrG (C) display 
Tm values of approximately 65°C, while PcrG (B) does not 
unfold in a cooperative manner.Page 4 of 9
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PcrV:PcrG complex displays a high thermostability as
shown by cooperative unfolding with an approximate Tm
of 65°C (Fig. 4c), as in the case of PcrV alone.
PcrV binds PcrG in a high affinity 1:1 complex
Interactions between PcrV and PcrG (full-length and 1–
74) were studied by surface plasmon resonance using the
BIAcore technology. When injected over the surface of the
sensor chip, PcrV was found to bind both specifically and
in a concentration-dependent manner to immobilized
PcrG (Fig. 5a). This set of sensorgrams was best fit to the
1:1 Langmuir binding model with drifting baseline
(chi2:0.43). The addition of a drifting term was required
to take into account the baseline drift due to buffer injec-
tion performed before PcrV injection. The corresponding
affinity constant KD, describing the interaction of PcrV
with the full length form of immobilized PcrG, was found
to be 1.56 × 10-8M. Notably, as shown in Fig. 5b, the
kinetics for the binding of PcrV to immobilized PcrG (1–
74) were similar to those for PcrG. The best fit of this latter
set of sensorgrams was also obtained using the 1:1 Lang-
muir binding model with drifting baseline. The corre-
sponding affinity constant KD, describing the interaction
of PcrV with immobilized PcrG (1–74), was also found to
be 1.56 × 10-8 M. The two affinity constants, in the
nanomolar range, indicate the formation of a high affinity
complex between PcrV and the first 74 residues of PcrG.
Although PcrV:PcrG and PcrV:PcrG(1–74) complexes
exhibited the same affinity, their association and dissoci-
ation rate constants displayed slight differences. PcrV
binds more rapidly to full length PcrG than to the trun-
cated form (ka(1–98) = 4.45 × 105 M-1 s-1, ka(1–74) = 3.16 ×
105 M-1 s-1), but the dissociation rate from the full length
form of PcrG is faster than from PcrG (1–74) (kd(1–98) =
6.94 × 10-3 s-1, kd(1–74) = 4.91 × 10-3s-1). No significant var-
iation in the association phase was observed when PcrV
was injected over either form of PcrG at different flow
rates, suggesting that mass transfer did not significantly
influence these interactions. This confirmed the kinetic
analysis that showed no improvement of the fit when a
mass transfer term was included in the model.
Discussion
Virulence in Pseudomonas aeruginosa strains has been
shown to be highly dependent on the expression of PcrV,
a soluble protein which can be found both in the bacterial
cytoplasm and in the extracellular region [8,9]. PcrV is
required for lung injury and cytotoxicity, and anti-PcrV
antibodies have been shown to be protective against infec-
tion, leading to increased macrophage survival in in vitro
and in vivo studies. These observations are directly linked
to the fact that PcrV is required for the translocation of
toxins into target cells, and neutralization of the
extracellular form of the protein by antibodies blocks
toxin injection and facilitates phagocytosis of Pseu-
domonas by macrophage cell lines [9].
In Yersinia, the homologous LcrV:LcrG complex plays a
key role in type III secretion. LcrG has been proposed to
block the secretion apparatus from the inner face of the
bacterial membrane, being titrated away from a yet-to-be-
determined partner within the secreton by high levels of
LcrV transcribed once secretion permissive conditions are
in place [16,18]. In Pseudomonas, however, ∆pcrV mutants
are able to secrete effectors in inducing or in non-inducing
conditions [9,24], suggesting that a PcrV:PcrG regulatory
mechanism may greatly differ from the well studied
LcrV:LcrG process. In this work, we have characterized the
PcrV:PcrG interaction by expressing and purifying both
PcrV and PcrG in soluble forms, and have shown that they
associate in a complex which can be isolated by gel filtra-
tion. Native mass spectrometry studies showed that PcrV
is a monomeric molecule, and its quaternary structure is
thus distinct for that determined for LcrV, which has been
reported to be dimeric [24]. In addition, our native mass
spectrometry results also show that the PcrV:PcrG com-
plex associates in 1:1 fashion (as does LcrV:LcrG; [24]), a
result confirmed by surface plasmon resonance
experiments.
Circular dichroism and limited proteolysis studies
showed that PcrG is highly unstable, presenting a low
level of secondary structure when in unbound form. How-
ever, it is stabilized through complexation with PcrV,
which is evidenced by a greater amount of α-helical struc-
ture in the PcrV:PcrG complex than in PcrV alone. The
contribution of PcrG to the overall compactness of the
complex may be minimal, however, as seen by the fact
that the Tm values are identical for PcrV and PcrV:PcrG.
These observations suggest that PcrG may not exist as an
unbound molecule within the bacterial cytoplasm. In
order to understand the kinetics and binding affinities
between PcrV and different regions of the PcrG molecule,
we performed surface plasmon resonance studies by
flowing PcrV over both full-length PcrG (residues 1–98)
as well as a truncated PcrG version (residues 1–74), since
PcrG residues 75–98 lack major secondary structural ele-
ments in prediction profiles. PcrV associates to and disso-
ciates from either form of PcrG relatively rapidly; this
would be expected if the PcrV:PcrG interaction were a
transient one, necessary uniquely for the establishment of
a regulatory response. In addition, the similarity in kinetic
parameters for the interaction of PcrV with both PcrG
forms coupled to the fact that binding of PcrV to either
form of PcrG presents the same affinity constant (KD 15.6
nM) suggests that the C-terminal region of PcrG (residues
75–98) does not participate in complex formation (an
observation which is in agreement with results obtainedPage 5 of 9
(page number not for citation purposes)
BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/21by Matson & Nilles [20] for the LcrV:LcrG interaction).
The fact that PcrV is able to bind to such an unstable mol-
ecule as PcrG with nanomolar affinity suggests a key role
for the PcrV:PcrG complex in regulation of type III secre-
tion in Pseudomonas.
Most affinity constants determined by surface plasmon
resonance in this work differ from those determined for
the Yersinia LcrV:LcrG interaction by the same technique
[24]. The ka reported for the formation of the LcrV:LcrG
complex is 100 times lower than that found for the Pseu-
domonas proteins (4.38 × 103 M-1s-1 versus 3.16–4.45 × 105
M-1s-1). In addition, the KD values reported for the
PcrV:PcrG complex are approximately 10 times lower
than those measured for the LcrV:LcrG interaction
(approximately 140 nM). Consequently, PcrV and PcrG
associate more rapidly and with a higher affinity than
their Yersinia counterparts, reinforcing the theory that the
PcrV binding to PcrG and PcrG (1–74) demonstrated by surface plasmon resonanceFigure 5
PcrV binding to PcrG and PcrG (1–74) demonstrated by surface plasmon resonance. Injection of PcrV (2–180 nM, 
flow rate: 40 µl/min, injected volume: 160 µl) over (A) immobilized PcrG (213 RU); (B) immobilized PcrG (1–74) (548 RU). 
Non-specific binding to the sensor chip (evaluated on flow cell 1) and the bulk effect due to the buffer were subtracted from 
the raw data.Page 6 of 9
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domonas may be distinct. In order to characterize this dif-
ference, further analysis of PcrV:PcrG interactions, as well
as the phenotypic analysis of ∆pcrG strains, will provide
essential information.
Conclusions
PcrV is a key component of the type III secretion system in
Pseudomonas, and its interaction with PcrG in the bacterial
cytoplasm may be a crucial factor for toxin secretion. PcrV,
a monomeric molecule, forms a 1:1 complex with PcrG.
Interestingly, PcrG is a highly unstable molecule, as seen
by temperature scanning circular dichroism, but forms a
stable complex with PcrV. The two molecules associate
with rapid kinetics and form a high affinity complex (KD
15.6 nM); in this association, the C-terminal region of
PcrG does not play a role. In Yersinia, LcrV is a dimeric
molecule which associates with its cognate LcrG with a KD
that is 10 fold weaker. Such distinctions are in agreement
with results from the phenotypic characterization of pcrv
mutant strains, which suggests that the regulatory role
played by the PcrV:PcrG complex is different from the one
proposed for its Yersinia counterpart.
Methods
Expression vectors and cloning
DNA fragments encoding full-length PcrV and full-length
PcrG (residues 1–98; henceforth referred to as PcrG) were
amplified by PCR using QBioTaq polymerase (QBio-
gene), cloned in pGEM-T (Promega) and verified by dou-
ble-stranded sequencing. The template plasmid for all
reactions was pIA60, a pUC18 derivative containing oper-
ons pcrGVHpopBD and exsCBA on an 8 kb EcoRI fragment
isolated from the P. aeruginosa strain CHA [22]. NdeI-
BamHI fragments were cloned into pET15b (Novagen),
generating pET/V and pET/G and placing the coding
region for a six histidine sequence (6His tag) upstream
from the coding regions of PcrV and PcrG, respectively.
During this study, we found that PcrV contained a
Ser225Arg mutation when compared to the available
sequence. This change was confirmed by direct sequenc-
ing of the PCR product obtained with genomic DNA as a
template, suggesting that the change is strain-specific.
The vector expressing the short form of PcrG (residues 1 to
74), pcrgs/pHIS8, was constructed by PCR amplification
of the desired region from construct pET/G (described
above). A NcoI-BamHI fragment was subsequently cloned
into vector pHIS8 upstream from a polyhistidine-encod-
ing tail.
Expression and purification of PcrV, PcrG, PcrG (1–74), 
and the PcrV:PcrG complex
PcrV production was performed as in [25] with minor
modifications. Briefly, expression of PcrV was induced in
E. coli strain BL21(DE3) in Terrific broth (Sigma) with 1
mM isopropyl-beta-D-thiogalactopyranoside (IPTG) for 5
h at 37°C. Cells were harvested by centrifugation and
lysed by sonication in lysis buffer (50 mM Tris-HCl pH
8.0, 0.5 M NaCl, 5 mM imidazole, 10 mM benzamidine).
The supernatant was cleared by centrifugation at 18,000
rpm and applied to a 1.5 mL Ni NTA agarose column
(Qiagen). Non-specifically bound protein was washed off
the resin with 20 column volumes of wash buffer (50 mM
Tris pH 8.0, 0.5 M NaCl, 20 mM imidazole). PcrV was
then eluted with 8 column volumes of elution buffer (50
mM Tris pH 8.0, 0.5 M NaCl, 250 mM imidazole), con-
centrated on a Centriprep concentration device (Amicon),
and loaded onto a gel filtration column (Amersham
HiLoad 16/60) previously equilibrated in 25 mM Tris pH
8.0, 50 mM NaCl, 1 mM EDTA. The hexahistidine tag was
removed by adding thrombin at a 1:400 ratio (w/w) for 1
hour; the reaction was stopped with 1 mM PMSF.
For PcrG and PcrG (1–74), most purification steps were
similar, with the exception that protein expression was
induced by adding 1 mM IPTG to bacterial cultures at
22°C for an overnight period. Either form of isolated PcrG
was clearly less stable than PcrV, presenting signs of
degradation after a few days of storage. Generation of the
PcrV:PcrG complex was performed by mixing approxi-
mately equal ratios of PcrV and PcrG, followed by gel fil-
tration chromatography. Protein concentration was
determined by UV absorption, and pure protein was
stored at 4° for up to 2 weeks.
Circular dichroism
PcrV, PcrG and the PcrV:PcrG complex were diluted to
0.35, 0.25 and 0.25 mg/mL, respectively, and dialyzed
against 20 mM phosphate buffer, pH 7.0 for 16 hours. CD
measurements were performed on a Jasco J-810 spectrom-
eter equipped with a PTC-423S temperature controller.
Melting curves were performed at 222 nm with a temper-
ature slope of 1°C/minute from 4° to 95°C. Data was
processed using Spectra Manager and Spectra Analysis ver-
sion 1.51 (Jasco). A CD spectrum of the phosphate buffer
alone was subtracted from all subsequent CD spectra. The
measured ellipticity was converted into molar ellipticity.
The percentage of helical content was estimated from
θ222nm by assuming that a value of -33,000
degrees.cm2.dmol-1 corresponds to 100% alpha helical
content [23].
Surface Plasmon Resonance (SPR) studies
Binding analysis was performed using a BIAcore 3000 sys-
tem (BIAcore AB, Uppsala, Sweden). PcrG and PcrG (1–
74) were covalently coupled to CM5 sensor chips
(Research grade) via amine coupling (amine coupling kit,
BIAcore AB). Initially, the carboxymethylated dextran sur-
face was activated by a 50 µl-injection of a mixture of 0.2Page 7 of 9
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0.05 M N-hydroxysuccinimide. PcrG was then injected in
10 mM maleate buffer pH 6.0 containing 25 mM sodium
chloride. Activation time, PcrG concentration and contact
time were adjusted according to the desired extent of
immobilization. Remaining N-hydroxysuccinimide esters
were blocked by the injection of 1 M ethanolamine hydro-
chloride pH 8.5. All immobilization steps were performed
at a flow rate of 5 µl/min.
The control flow cell was prepared by carrying out the
coupling reaction in the presence of coupling buffer
alone. It was used to obtain control sensorgrams showing
non-specific binding of PcrV to the surface. Sample buffer
was injected over the different flow cells to monitor refrac-
tive index changes. Control sensorgrams were then sub-
tracted from sensorgrams obtained with immobilized
PcrG in order to yield true binding responses.
Binding assays were performed at 25°C in 10 mM HEPES
buffer pH 7.4 containing 0.15 M NaCl and 0.005% (v/v)
P20 surfactant (HBS-P buffer, BIAcore AB, Uppsala, Swe-
den). PcrV was dialyzed against HBS-P buffer and injected
at several concentrations and different flow rates over
immobilized PcrG and PcrG (1–74). The surface was then
regenerated with a pulse (30 µl) of 3 M guanidinium chlo-
ride. Kinetic constants were calculated by non-linear fit-
ting to the association and dissociation curves
(BIAevaluation 3.1 software). Apparent equilibrium dis-
sociation constants (KD) were then calculated as the ratio
of kd/ka.
Mass spectrometry
Non-covalent mass spectrometry measurements were per-
formed by using a Q-TOF Micro mass spectrometer
(Micromass, Manchester, U. K.) equipped with an electro-
spray ion source operating with a needle voltage of 2.7 kV
and sample cone voltage of 30 V. PcrV and PcrV:PcrG were
prepared in 15 mM ammonium bicarbonate pH 7.8 at a
final concentration of 20 µM and were continuously
infused at a flow rate of 10 µL/min. The mass spectra were
recorded in the 1500–3700 mass-to-charge (m/z) range.
Data were acquired in the positive mode and calibration
was performed using the multiply charged states pro-
duced by a separate injection of heart horse myoglobin
dissolved in water/acetonitrile (1:1-v/v) with 0.2% formic
acid. Data were processed with MassLynx 4.0
(Micromass).
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